OncoMatch/Clinical Trials/NCT07193966
NG2 and DLL3 CAR-T Cells Targeting Melanoma
Is NCT07193966 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1/2 trial studies NG2 and DLL3 CAR-T cells for melanoma.
Treatment: NG2 and DLL3 CAR-T cells — The purpose of this study is to assess the feasibility, safety and efficacy of multiple CAR-T cell therapy which targets NG2 and DLL3 surface antigens in patients with relapsed and refractory melanoma.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Melanoma
Biomarker criteria
Required: CSPG4 positive expression (positive)
Required: DLL3 positive expression (positive)
Disease stage
Metastatic disease required
Demographics
Prior therapy
Must have received: standard first-line therapy
Patients with tumors have received standard first-line therapy and have been diagnosed with non-resectable, metastatic, progressive or recurrent conditions.
Cannot have received: genetically engineered CAR T cells
Previous treatment with other genetically engineered CAR T cells.
Lab requirements
Blood counts
WBC ≥1000/ul, ANC ≥500/ul, ALC ≥500/ul, Platelet count ≥25,000/ul (not achieved by transfusion)
Kidney function
serum creatinine less than 3 times ULN
Liver function
ALT <3x ULN, AST <3x ULN; serum bilirubin and alkaline phosphatase <2x ULN
Cardiac function
Left ventricular ejection fraction ≥40/55 percent
Liver function: defined as alanine transaminase (ALT) <3x upper limit of normal (ULN), aspartate aminotransferase (AST) <3x ULN; serum bilirubin and alkaline phosphatase <2x ULN. Renal function: Patients must have serum creatinine less than 3 times ULN. Marrow function: White blood cell count ≥1000/ul, Absolute neutrophil count ≥500/ul, Absolute lymphocyte count ≥500/ul, Platelet count ≥25,000/ul (not achieved by transfusion). Cardiac function: Left ventricular ejection fraction greater than or equal to 40/55 percent. Pulse Ox greater than or equal to 90% on room air.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07193966 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior genetically engineered CAR T cells disqualifies patients from enrollment.
Does this trial require CSPG4?
Yes, CSPG4 positive expression is a required biomarker for enrollment.
Does this trial require DLL3?
Yes, DLL3 positive expression is a required biomarker for enrollment.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages